Amicus Therapeutics US, LLC et al v. Lupin Ltd. et al
Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc. |
Lupin Ltd. and Lupin Pharmaceuticals, Inc. |
1:2023cv00964 |
September 1, 2023 |
US District Court for the District of Delaware |
Christopher J Burke |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 Patent Infringement |
None |
Docket Report
This docket was last retrieved on October 20, 2023. A more recent docket listing may be available from PACER.
Document Text |
---|
Pro Hac Vice Attorneys Joshua E. Ney, Mark C. Nelson, and Christina M. Baugh for Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
|
|
Filing 18 STIPULATION TO EXTEND TIME to Submit Case Management Checklist to November 15, 2023 - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) |
Filing 17 MOTION for Pro Hac Vice Appearance of Attorney John W. Cox, Ph.D., Mark C. Nelson, Christina M. Baugh, Joshua E. Ney, Ph.D., Heather B. Repicky, Joshua M. Kalb, Lauren Baker and Anna Whitacre - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc.. (Stover, Chad) |
Filing 16 ANSWER to #9 Answer to Complaint, Counterclaim by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) |
Filing 15 NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures and Lupin Limited and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Amended Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Bilson, David) |
Filing 14 NOTICE OF SERVICE of 1) Plaintiffs Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.'s Disclosure Pursuant to Paragraph 3 of the Default Standard for Discovery and 2) Plaintiffs Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) |
Filing 13 NOTICE OF SERVICE of Plaintiffs Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.'s Preliminary Disclosure of Asserted Claims filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc..(Stover, Chad) |
|
Remark: The parties should follow the Court's Standing Order Regarding Courtesy Copies, a copy of which is found on Judge Burke's portion of the District Court's webpage: #https://www.ded.uscourts.gov/sites/ded/files/CJBCC2022.pdf (dlb) |
REMARK: The parties should be aware that the Court encourages the participation of newer attorneys in courtroom proceedings and at oral argument. Please see the Court's Standing Order Regarding Courtroom Opportunities for Newer Attorneys, a link to which is provided here for the parties' convenience:#http://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrder2017.pdf (dlb) |
Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited for Lupin Pharmaceuticals, Inc. filed by Lupin Pharmaceuticals, Inc.. (Phillips, John) |
Filing 10 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Lupin Ltd.. (Phillips, John) |
Filing 9 ANSWER to #1 Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Lupin Pharmaceuticals, Inc., Lupin Ltd..(Phillips, John) |
Filing 8 CONSENT to Jurisdiction by U.S. Magistrate Judge filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. Case reassigned to Magistrate Judge Christopher J. Burke. Signed by Judge Colm F. Connolly on 9/19/2023. (nmf) |
|
Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
Filing 7 Summons Issued as to Lupin Ltd. and Lupin Pharmaceuticals, Inc. on 9/1/2023. (Attachments: #1 Summons Issued Lupin Pharmaceuticals, Inc.)(jfm) |
Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed for Amicus Therapeutics, Inc. filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (jfm) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amicus Therapeutics, Inc. for Amicus Therapeutics US, LLC filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (jfm) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,000,011; 9,987,263; 10,383,864; 10,406,143; 10,925,866; 10,813,921; RE48,608. (jfm) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: August 10, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/10/2026. (jfm) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) |
Filing 1 COMPLAINT filed against Lupin Ltd., Lupin Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4214674.) - filed by Amicus Therapeutics US, LLC, Amicus Therapeutics, Inc. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G, #8 Civil Cover Sheet)(jfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.